Study Supports Observation Only for Most Low-Risk Prostate CA

Share this content:
Study Supports Observation Only for Most Low-Risk Prostate CA
Study Supports Observation Only for Most Low-Risk Prostate CA

THURSDAY, July 13, 2017 (HealthDay News) -- Men with early-stage prostate cancer who have surgery to remove their tumor do not live longer than those who receive no treatment at all, according a study published in the July 13 issue of the New England Journal of Medicine.

Timothy Wilt, M.D., M.P.H., a clinical investigator with the Minneapolis Veterans Affairs Health Care System, and colleagues randomly assigned 731 men with low-risk prostate cancer to either undergo surgery or observation only.

Of the men who underwent prostate cancer surgery, 223 (61.3 percent) died during as much as two decades of follow-up, compared with 245 men (66.8 percent) placed on observation. The difference was not statistically significant, the researchers noted. In addition, 27 men (7.4 percent) in the surgery group died of prostate cancer, compared with 42 men (11.4 percent) in the observation group. That difference also was not statistically significant, according to the investigators. At the same time, nearly one in three men who had the surgery experienced long-term complications, such as urinary incontinence and erectile dysfunction, Wilt told HealthDay.

"Our results demonstrate that for the large majority of men with localized prostate cancer, selecting observation for their treatment choice can help them live a similar length of life, avoid death from prostate cancer and prevent harms from surgical treatment," Wilt said.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

High Costs Associated With Physician Burnout, Attrition

High Costs Associated With Physician Burnout, Attrition

Economic loss at Stanford over two years expected to range from $15.5 million to $55.5 million

Insulin Doesn't Prevent Diabetes in Relatives of T1DM Patients

Insulin Doesn't Prevent Diabetes in Relatives of T1DM ...

Oral insulin doesn't delay onset in autoantibody-positive relatives of patients with type 1 diabetes

Workplace Sexual Harassment Ongoing in Women, Up for Men

Workplace Sexual Harassment Ongoing in Women, Up for ...

Women report more adverse effects after SH than men, but SH can trigger depression, anxiety in men

is free, fast, and customized just for you!

Already a member?

Sign In Now »